- Home
- OOMA vs ACIU Comparison
OOMA vs ACIU Comparison
Compare OOMA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OOMA
- ACIU
- Stock Information
- Founded
- OOMA 2003
- ACIU 2003
- Country
- OOMA United States
- ACIU Switzerland
- Employees
- OOMA N/A
- ACIU N/A
- Industry
- OOMA EDP Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- OOMA Technology
- ACIU Health Care
- Exchange
- OOMA Nasdaq
- ACIU Nasdaq
- Market Cap
- OOMA 345.3M
- ACIU 213.3M
- IPO Year
- OOMA 2015
- ACIU 2016
- Fundamental
- Price
- OOMA $12.69
- ACIU $2.41
- Analyst Decision
- OOMA Strong Buy
- ACIU Strong Buy
- Analyst Count
- OOMA 5
- ACIU 2
- Target Price
- OOMA $17.63
- ACIU $10.00
- AVG Volume (30 Days)
- OOMA 189.9K
- ACIU 132.0K
- Earning Date
- OOMA 08-26-2025
- ACIU 11-04-2025
- Dividend Yield
- OOMA N/A
- ACIU N/A
- EPS Growth
- OOMA N/A
- ACIU N/A
- EPS
- OOMA N/A
- ACIU N/A
- Revenue
- OOMA $261,617,000.00
- ACIU $36,362,036.00
- Revenue This Year
- OOMA $6.33
- ACIU N/A
- Revenue Next Year
- OOMA $6.15
- ACIU $1,022.98
- P/E Ratio
- OOMA N/A
- ACIU N/A
- Revenue Growth
- OOMA 5.42
- ACIU 86.71
- 52 Week Low
- OOMA $10.88
- ACIU $1.43
- 52 Week High
- OOMA $17.00
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- OOMA 54.86
- ACIU 62.73
- Support Level
- OOMA $12.43
- ACIU $2.12
- Resistance Level
- OOMA $12.83
- ACIU $2.35
- Average True Range (ATR)
- OOMA 0.40
- ACIU 0.13
- MACD
- OOMA -0.02
- ACIU 0.04
- Stochastic Oscillator
- OOMA 24.44
- ACIU 91.49
About OOMA Ooma Inc.
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.